[go: up one dir, main page]

WO2001074847A3 - Epitope de lymphocyte t de mage-12 et acides nucleiques, vecteurs et cellules correspondants, compositions et procedes induisant une reaction immunitaire a un cancer - Google Patents

Epitope de lymphocyte t de mage-12 et acides nucleiques, vecteurs et cellules correspondants, compositions et procedes induisant une reaction immunitaire a un cancer Download PDF

Info

Publication number
WO2001074847A3
WO2001074847A3 PCT/US2001/010312 US0110312W WO0174847A3 WO 2001074847 A3 WO2001074847 A3 WO 2001074847A3 US 0110312 W US0110312 W US 0110312W WO 0174847 A3 WO0174847 A3 WO 0174847A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
immune response
inducing
mammal
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/010312
Other languages
English (en)
Other versions
WO2001074847A2 (fr
Inventor
Monica Panelli
Maria Bettinotti
Francesco Marincola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to AU2001253029A priority Critical patent/AU2001253029A1/en
Publication of WO2001074847A2 publication Critical patent/WO2001074847A2/fr
Publication of WO2001074847A3 publication Critical patent/WO2001074847A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un polypeptide isolé et purifié constitué essentiellement de la séquence d'acides aminés VRIGHLYIL, une molécule d'acide nucléique isolée et purifiée constituée essentiellement d'une séquence nucléotidique codant pour la séquence d'acides aminés VRIGHLYIL, telle que SEQ ID NO:2, un vecteur contenant et exprimant cette molécule d'acide nucléique isolée et purifiée et une cellule contenant ce vecteur. L'invention concerne en outre une composition renfermant le polypeptide isolé et purifié ou le vecteur dans une quantité capable d'induire chez un mammifère une réaction immunitaire à l'égard du polypeptide, ainsi qu'un procédé visant à induire chez un mammifère atteint de cancer, p. ex. de mélanome, une réaction immunitaire à un cancer. Le procédé comporte l'administration au mammifère de cette composition, qui contient de préférence HLA-Cw*0702, dans une quantité capable d'induire chez ce mammifère une réaction immunitaire au cancer. Le procédé peut comporter en outre l'administration d'une cytokine telle que l'interleukine 2.
PCT/US2001/010312 2000-03-30 2001-03-29 Epitope de lymphocyte t de mage-12 et acides nucleiques, vecteurs et cellules correspondants, compositions et procedes induisant une reaction immunitaire a un cancer Ceased WO2001074847A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001253029A AU2001253029A1 (en) 2000-03-30 2001-03-29 T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19320600P 2000-03-30 2000-03-30
US60/193,206 2000-03-30

Publications (2)

Publication Number Publication Date
WO2001074847A2 WO2001074847A2 (fr) 2001-10-11
WO2001074847A3 true WO2001074847A3 (fr) 2002-03-21

Family

ID=22712651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010312 Ceased WO2001074847A2 (fr) 2000-03-30 2001-03-29 Epitope de lymphocyte t de mage-12 et acides nucleiques, vecteurs et cellules correspondants, compositions et procedes induisant une reaction immunitaire a un cancer

Country Status (2)

Country Link
AU (1) AU2001253029A1 (fr)
WO (1) WO2001074847A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103974974A (zh) * 2011-09-15 2014-08-06 美国卫生和人力服务部 识别hla-a1-或hla-cw7-限制的mage的t细胞受体
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031017A1 (fr) * 1996-02-20 1997-08-28 Ludwig Institute For Cancer Research Antigenes de rejet tumoral presentes par des molecules hla-b44 et utilisations de ces derniers
WO1999045954A1 (fr) * 1998-03-13 1999-09-16 Epimmune, Inc. Peptides de liaison de hla et leurs applications
WO1999061916A1 (fr) * 1998-05-29 1999-12-02 Epimmune, Inc. Identification d'epitopes dr de restriction largement reactifs
WO2000052045A2 (fr) * 1999-02-26 2000-09-08 Fondazione Centro San Raffaele Del Monte Tabor Peptides immunogenes derives de mage-3 presentes par le complexe majeur d'histocompatibilte (mch) de categorie ii et utilisations associees
WO2001000225A1 (fr) * 1999-06-29 2001-01-04 Epimmune Inc. Peptides de liaison a hla et leurs utilisations
WO2001029220A2 (fr) * 1999-10-19 2001-04-26 Ludwig Institute For Cancer Research Peptides antigeniques mage-a12 et utilisation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031017A1 (fr) * 1996-02-20 1997-08-28 Ludwig Institute For Cancer Research Antigenes de rejet tumoral presentes par des molecules hla-b44 et utilisations de ces derniers
WO1999045954A1 (fr) * 1998-03-13 1999-09-16 Epimmune, Inc. Peptides de liaison de hla et leurs applications
WO1999061916A1 (fr) * 1998-05-29 1999-12-02 Epimmune, Inc. Identification d'epitopes dr de restriction largement reactifs
WO2000052045A2 (fr) * 1999-02-26 2000-09-08 Fondazione Centro San Raffaele Del Monte Tabor Peptides immunogenes derives de mage-3 presentes par le complexe majeur d'histocompatibilte (mch) de categorie ii et utilisations associees
WO2001000225A1 (fr) * 1999-06-29 2001-01-04 Epimmune Inc. Peptides de liaison a hla et leurs utilisations
WO2001029220A2 (fr) * 1999-10-19 2001-04-26 Ludwig Institute For Cancer Research Peptides antigeniques mage-a12 et utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEIDECKER, LEONORA ET AL: "Cytolytic T lymphocytes raised against a human bladder carcinoma recogniz an antigen encoded by gene MAGE-A12", J. IMMUNOL. (2000), 164(11), 6041-6045, XP002173646 *
PANELLI, MONICA C. ET AL: "A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12", J. IMMUNOL. (2000), 164(8), 4382-4392, XP002173647 *
PLAEN DE E ET AL: "STRUCTURE, CHROMOSOMAL LOCALIZATION, AND EXPRESSION OF 12 GENES OF THE MAGE FAMILY", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 40, no. 5, 1994, pages 360 - 369, XP000614537, ISSN: 0093-7711 *

Also Published As

Publication number Publication date
AU2001253029A1 (en) 2001-10-15
WO2001074847A2 (fr) 2001-10-11

Similar Documents

Publication Publication Date Title
WO2002020766A3 (fr) Compositions d'analogues de g-csf et procedes correspondants
CA2248667A1 (fr) Peptides de fixation de hla-a2.1 et leurs utilisations
EP0930365A3 (fr) Domaines de liaison de la protéine serrate
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
JP2002535956A5 (fr)
ES2009238A6 (es) Metodo para producir proteinas de mycobacterium tuberculosis y peptidos antigenicos de las mismas.
WO1998004702A3 (fr) Proteines, notamment proteines membranaires, d'helicobacter pylori, leur preparation et utilisation
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
CA2249233A1 (fr) Codage des apotose proteases mch4 et mch5 par des acides nucleiques, et methodes d'utilisation
CA2461443A1 (fr) Sequences d'acides nucleiques et d'acides amines codant des polypeptides de facteur viii a expresseur a haut rendement et leurs procedes d'utilisation
WO2000026244A3 (fr) Nouveau membre de la famille des facteurs de necrose des tumeurs, ligand du recepteur de la mort cellulaire (drl) et compositions et procedes correspondants
WO2002008426A3 (fr) Proteine
NZ332565A (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
WO2005118627A3 (fr) Griffithsin, griffithsin resistante a la glycosylation, conjugues, compositions, acides nucleiques, vecteurs, cellules hotes, et methodes de production et d'utilisation associes
AU6724794A (en) GRB3-3 gene, its variants and their uses
NZ334568A (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
AU5776799A (en) Modified hcv peptide vaccines
WO2001074847A3 (fr) Epitope de lymphocyte t de mage-12 et acides nucleiques, vecteurs et cellules correspondants, compositions et procedes induisant une reaction immunitaire a un cancer
DK0773999T3 (da) OR-1, en orphan-receptor tilhørende kernereceptorfamilien
WO2003097677A3 (fr) Nouvelles compostions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
MXPA03010527A (es) Composicion de vacuna.
WO2005058944A3 (fr) Peptides immunogenes de xage-1
WO2004099244A3 (fr) Tnf detoxifie et technique de preparation
WO2004056316A3 (fr) Vaccins contre la proteine tat de vih servant a generer des anticorps neutralisants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP